Valeant second-quarter total revenue increases 86%

Valeant Pharmaceuticals reported a total revenue of $2 billion for the second quarter of 2014, up 86% from the second quarter of 2013. The company’s net income was $126 million, or $0.37 per diluted share. Based on cash earnings per share, Valeant’s adjusted income increased by 43% from the previous year at $651 million, or $1.91 per diluted share, according to a company press release.

Full Story →